SBIR/STTR Research Award

Protease Indicator for Chronic Wound Management

Award identifier e18453408adb7072ff0d4c7ae399f84abbed82a95758a66672be86d15912a02aAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$118,604

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIO-SENSE, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Chronic wounds are characterized by an overabundant presence of polymorphonuclear leukocytes(PMN's) which produce excessive elastase and the PMN collagenase , MMP-8. Collagenase destroys the wound matrix while elastase degrades growth factors and their receptor sites. These excessive proteases can be lowered by radical surgical debridement of the wound to promote healing. Once the wound proteases are lowered, host growth factors will be functional and/or the clinician can add extrinsic growth factors to the wound without degradation by these deleterious enzymes. More recently, protease sequestering dressings have been developed to lower protease content for improve healing. However, determination that the protease level has been lowered requires laboratory study of wound fluids or biopsies with at least a 24hour delay before the information is returned to the clinician. Using the methodology to be developed in this proposal, a rapid, safe, inexpensive bed-side measurement of collagenase and elastase can be made which will determine when the protease sequestering dressing can be stopped safely. At present the decision to change to another form of dressing is made imperically by simply observing the appearance of the wound. Two approaches will be evaluated. The first approach will be to assay both proteases using rapid immunochromatographic methods. The second approach will be to assay elastase by a rapid colorimetric or fluorometric method. The methods will be validated using purified proteins, artificial wound fluids, and patient wound fluid samples. The assays used to develop this product are standard and should lead to a commercial product development in a Phase II study. Commercial production of the device and FDA approval as such should be straight forward . Cost of production will be low and therefore, broad usage and company profit is expected. The benefits to our patient population with chronic wounds should be significant.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.